Exploring New Treatment Strategies for Immune Checkpoint Blockade in Melanoma

Attend this live symposium in Atlanta to learn how experts are applying novel strategies in treating melanoma! Interact with the experts as they discuss best practices and emerging clinical data in an engaging, case-based format.

This symposium is sponsored by Clinical Care Options, LLC and supported by a grant from Merck & Co., Inc. This is not an official program of the American Association for Cancer Research Annual Meeting.

Agenda

Welcome, Introduction, and Baseline Assessment

State-of-the-Art Management of Node-Positive Melanoma After Resection with Immune Checkpoint Inhibitors

Contemporary Treatment Strategies for Resectable Melanoma: Is Earlier Immune Checkpoint Blockade Better?

Identifying and Managing Treatment-Related Adverse Events: Preserving Efficacy and Reducing Toxicity

Panel Discussion: 2019 Clinical Treatment Algorithm and Key Abstracts/Emerging Data Sets

Events

Date / Time
Event Details

Faculty

Faculty
Rodabe Amaria, MD

Assistant Professor
Department of Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Faculty
Michael B. Atkins, MD

Deputy Director
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Faculty
Ahmad Tarhini, MD, PhD

Acting Professor, Hematology and Medical Oncology
Emory University School of Medicine
Co-Director, Melanoma and Skin Cancer Program
Winship Cancer Institute of Emory University
Atlanta, Georgia

Target Audience 
This program is intended for oncologists and other healthcare professionals involved in the treatment of melanoma.

Learning Objectives 

  • Plan optimal adjuvant treatment strategies for patients with melanoma at high risk of recurrence after surgical resection based on available data and expert recommendations
  • Evaluate the available clinical data on neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
  • Manage adverse events effectively in patients receiving novel targeted agents or immunotherapies for melanoma based on available data, recommendations, and available decision support tools
  • Identify patients with advanced melanoma suitable for enrollment on ongoing clinical studies investigating novel therapies or combination strategies

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.